NU 578 Unit 5 Exam University Of South Alabama
EXAM COVERAGE
1. Pharmacokinetic and Pharmacodynamic Principles in Advanced Prescribing
2. Drug Metabolism, CYP450 Interactions, and Pharmacogenomics
3. Autonomic Nervous System Pharmacology and Receptor Selectivity
4. Cardiovascular Pharmacology: Antihypertensives, Antiarrhythmics, and Heart
Failure Agents
5. Central Nervous System Pharmacology: Antidepressants, Anxiolytics, and
Anticonvulsants
6. Opioid Analgesics, Controlled Substances, and Pain Management Guidelines
7. Antimicrobial Therapy: Mechanisms of Resistance and Clinical Application
8. Endocrine Pharmacology: Insulin, Oral Hypoglycemics, and Thyroid Agents
9. Special Populations: Geriatrics, Pregnancy, Renal and Hepatic Impairment
10. Evidence-Based Guidelines and Safe Prescribing Practices
,NU 578 Unit 5 Exam University Of South Alabama
NU 578 Unit 5 Exam University Of South Alabama
1. A patient with a history of opioid use disorder is initiated on
buprenorphine/naloxone. Which pharmacodynamic property best explains the
ceiling effect on respiratory depression observed with this medication?
A. High intrinsic efficacy at the mu-opioid receptor
B. Partial agonist activity at the mu-opioid receptor
C. Competitive antagonism at the kappa-opioid receptor
D. Irreversible inhibition of the CYP3A4 enzyme system
Correct Answer: B
Rationale: Buprenorphine is a partial agonist at the mu-opioid receptor,
producing submaximal effects and a ceiling on respiratory depression. Full
agonists like methadone have higher efficacy and no ceiling effect. Kappa
antagonism and CYP inhibition do not account for this clinical phenomenon.
,2. Which cytochrome P450 enzyme is primarily responsible for the metabolic
activation of clopidogrel, and what is the clinical implication for patients
identified as poor metabolizers?
A. CYP2C19; reduced antiplatelet effect requiring alternative therapy
B. CYP3A4; increased bleeding risk requiring dose reduction
C. CYP2D6; increased antiplatelet effect requiring dose reduction
D. CYP1A2; no significant clinical effect requiring no adjustment
Correct Answer: A
Rationale: Clopidogrel is a prodrug activated by CYP2C19. Poor metabolizers
have reduced active metabolite formation and diminished antiplatelet effect,
increasing risk of cardiovascular events. Guidelines recommend alternative
therapy such as prasugrel or ticagrelor.
3. A patient on warfarin is prescribed trimethoprim-sulfamethoxazole for a
urinary tract infection. Which mechanism best explains the resulting increase
in INR observed in this patient?
A. Induction of CYP2C9 increasing warfarin metabolism
, B. Displacement of warfarin from albumin binding sites
C. Inhibition of CYP2C9 and reduction of vitamin K-producing gut flora
D. Increased renal clearance of warfarin leading to accumulation
Correct Answer: C
Rationale: Trimethoprim-sulfamethoxazole inhibits CYP2C9, reducing warfarin
metabolism, and suppresses gut flora that produce vitamin K, enhancing
anticoagulation. This dual mechanism significantly elevates INR. Displacement
and renal effects are less clinically significant.
4. Which statement accurately reflects the current ADA Standards of Care
regarding the use of SGLT2 inhibitors in patients with heart failure and type 2
diabetes mellitus?
A. They are contraindicated in heart failure due to fluid retention
B. They reduce hospitalization for heart failure and are recommended
independent of glycemic control
C. They should be used only if eGFR is above 60 mL/min/1.73 m²
EXAM COVERAGE
1. Pharmacokinetic and Pharmacodynamic Principles in Advanced Prescribing
2. Drug Metabolism, CYP450 Interactions, and Pharmacogenomics
3. Autonomic Nervous System Pharmacology and Receptor Selectivity
4. Cardiovascular Pharmacology: Antihypertensives, Antiarrhythmics, and Heart
Failure Agents
5. Central Nervous System Pharmacology: Antidepressants, Anxiolytics, and
Anticonvulsants
6. Opioid Analgesics, Controlled Substances, and Pain Management Guidelines
7. Antimicrobial Therapy: Mechanisms of Resistance and Clinical Application
8. Endocrine Pharmacology: Insulin, Oral Hypoglycemics, and Thyroid Agents
9. Special Populations: Geriatrics, Pregnancy, Renal and Hepatic Impairment
10. Evidence-Based Guidelines and Safe Prescribing Practices
,NU 578 Unit 5 Exam University Of South Alabama
NU 578 Unit 5 Exam University Of South Alabama
1. A patient with a history of opioid use disorder is initiated on
buprenorphine/naloxone. Which pharmacodynamic property best explains the
ceiling effect on respiratory depression observed with this medication?
A. High intrinsic efficacy at the mu-opioid receptor
B. Partial agonist activity at the mu-opioid receptor
C. Competitive antagonism at the kappa-opioid receptor
D. Irreversible inhibition of the CYP3A4 enzyme system
Correct Answer: B
Rationale: Buprenorphine is a partial agonist at the mu-opioid receptor,
producing submaximal effects and a ceiling on respiratory depression. Full
agonists like methadone have higher efficacy and no ceiling effect. Kappa
antagonism and CYP inhibition do not account for this clinical phenomenon.
,2. Which cytochrome P450 enzyme is primarily responsible for the metabolic
activation of clopidogrel, and what is the clinical implication for patients
identified as poor metabolizers?
A. CYP2C19; reduced antiplatelet effect requiring alternative therapy
B. CYP3A4; increased bleeding risk requiring dose reduction
C. CYP2D6; increased antiplatelet effect requiring dose reduction
D. CYP1A2; no significant clinical effect requiring no adjustment
Correct Answer: A
Rationale: Clopidogrel is a prodrug activated by CYP2C19. Poor metabolizers
have reduced active metabolite formation and diminished antiplatelet effect,
increasing risk of cardiovascular events. Guidelines recommend alternative
therapy such as prasugrel or ticagrelor.
3. A patient on warfarin is prescribed trimethoprim-sulfamethoxazole for a
urinary tract infection. Which mechanism best explains the resulting increase
in INR observed in this patient?
A. Induction of CYP2C9 increasing warfarin metabolism
, B. Displacement of warfarin from albumin binding sites
C. Inhibition of CYP2C9 and reduction of vitamin K-producing gut flora
D. Increased renal clearance of warfarin leading to accumulation
Correct Answer: C
Rationale: Trimethoprim-sulfamethoxazole inhibits CYP2C9, reducing warfarin
metabolism, and suppresses gut flora that produce vitamin K, enhancing
anticoagulation. This dual mechanism significantly elevates INR. Displacement
and renal effects are less clinically significant.
4. Which statement accurately reflects the current ADA Standards of Care
regarding the use of SGLT2 inhibitors in patients with heart failure and type 2
diabetes mellitus?
A. They are contraindicated in heart failure due to fluid retention
B. They reduce hospitalization for heart failure and are recommended
independent of glycemic control
C. They should be used only if eGFR is above 60 mL/min/1.73 m²
